Rare paralysis in some vaccine takers

|

It seems that this subdomain is turning into pure vaccine safety news digest. Unfortunately there are not so many vaccine news nowdays. Except, of course, the mass hysteria about flu vaccine for the coming winter.

So, 15 youngster are paralyzed after being vaccinated with Menactra, meningitis vaccine.

The CDC and the U.S. Food and Drug Administration issued a public statement yesterday through their Medwatch monitoring system saying Menactra may be associated with "a small increased risk" of Guillain-Barre Syndrome.
According to the CDC, Guillain-Barre causes loss of reflexes and temporary paralysis. Recovery usually begins within two to four weeks, although it may persist in some patients.

The whole article is below

Drug-safety officials and the vaccine-maker Sanofi Pasteur are studying reports of a rare paralysis condition among at least 15 young people among millions vaccinated with Menactra, its meningitis vaccine.

The cases of Guillain-Barre Syndrome, occurring six weeks after vaccinations, amounted to about 1.25 people out of one million vaccinated nationwide, according to officials at the U.S. Centers for Disease Control and Prevention.

An estimated 6.6 million doses of the vaccine, manufactured in Swiftwater, Pa., about 100 miles north of Philadelphia, have been administered since it was introduced in March 2005, the company said.

The CDC and the U.S. Food and Drug Administration issued a public statement yesterday through their Medwatch monitoring system saying Menactra may be associated with "a small increased risk" of Guillain-Barre Syndrome.

But, it added, the magnitude of the risk was unknown and appears far less than the risk of contracting meningitis itself, a potentially deadly infection.

"At the present time, there are no changes in recommendations for vaccination, and individuals should continue to follow their doctors' recommendations," the Medwatch statement said.

The Associated Press said a federal advisory committee on vaccines was expected to discuss the evidence this week.

"We take any adverse events very seriously," said Donna Cary, a spokeswoman at Sanofi Pasteur Inc. "But we do know that Guillain-Barre Syndrome occurs during the summer and that adolescents seem to be more at risk. Menactra is given to the same population, during the summer."

Sanofi Pasteur said Menactra sales worldwide produced revenue for the first half of this year of 119 million euros, a figure roughly equivalent to $149 million at exchange rates June 30.

According to the CDC, Guillain-Barre causes loss of reflexes and temporary paralysis. Recovery usually begins within two to four weeks, although it may persist in some patients

source